Member Info for chester18

Thanks to Ichor 18.5p is a "Premium Bargain" ...... : )

I don't think we would have dropped much below 22p or 23p if those 3.5 million shares hadn't been dumped.

Next news will hopefully see us start the journey back towards previous highs.

Meanwhile we still await news on a possible new senior management role.
Possible update on SCIB1 +Ci or even news of a deal on GlyMabs / AvidiMab. May even be the unparking of Covidity, you just never know.

Left Field anyone ??

Chester.

Hi crumbs

Yes I forgot about stage 4, memory T Cells.....

I think this debate about what DTH is and what it signifies has helped me understand the pace at which tumours will be slowed, stopped, regressed and finally cleared.
Maybe higher doses will speed things up and the brakes coming off with Checkpoint Inhibitors will help clear very stubborn tumours.

I'm very excited for the future progress of our trial.

Chester.

Hiya Ruck

We will need to wait and see if there is any correllation between the reaction ( swelling ) at the injection site and the devastation of the Tumour.....

As has been said by Wildforce the data from the Modi1 +Ci Cohort is going to be really interesting.

Such a lot of results to come from the next twelve months, should be fascinating.

Chester.

Anyway, 'Football is On' gotta go.......

The question is :
Is the swelling around the injection site measurable, as you can with an allergic reaction.

Answer: 'yes it is measurable'.

Also the creation of a DTH shows that the injection site is producing the required immune response. CD4 'T' Cells being created which then go off to seek their encoded targets.

If ModiTope has three stages we know that stage 1 is being achieved in 23 out of 23 patients.

Stage 2 is do CD4 Cytotoxic cells become activated in all 23 patients.

Stage 3, in what percentage of patients are those CD4 cytotoxic cells produced in enough quantity to over come the tumours growth and begin the process of clearing the tumour.

We now know that process will be gradual in most cases dependant on the patients own immune system 'strength' and the tumour environment type.

Simples......

Chester.

Another 1.5M sold today so we can safely say if it is Ichor then their 3 5M have all gone through.

We should now see the downward pressure come off the SP.

Chester.

Morning Bojo2020

I was just about to mention that.

You were actually trying to make a very good point. We have Cohort 1 patients that have been on the trial for an average of 7 months, Cohort 2 an average of 5 months and the expansion arm 3 months.

So Scancell have a range of data but all on different timelines.

There is the possibility that further data points can be RNS'd.
16 week scans End April, 24 week End of June and so on.

Between now and then we could have senior recruitment news, deals on Mabs, SCIB1 +Ci and fingers crossed news on where Covidity is heading.

Chester.

Thinking about it logically, Ichor will not want to own shares in a company that is about to sing the praises of a rival drug delivery system.

'PharmaJets Needle Free injection system'.

Chester.

If this is Ichor selling their 3M share options, yesterday's tally was only 1.5M. I'm hoping the rest has already gone through.

The MM's agree a price for the block of shares and then proceed to drop the price to entice buying. The SP reduction is controlled so that they eventually cover the agreed block and still take a margin.

If they are done the SP will naturally begin to rise but these transactions have switched the sentiment from positive to negative.

Hopefully there will be something from Scancell in the next weeks to bring back positivity.

Chester.

Hi Matt

Considering that around 54% of the shares are not in public hands, that means that us PI's hold around 450,000,000 shares.
Today's trading is only 500k bought and 500k sold roughly speaking.

There are plenty trading our shares and the Market Makers know how to influence more buys or more sells, that is after all their job.

I am surprised that more investors haven't jumped on the shares but 'Encouraging' is not a word that evokes excitement and some ( expecting big rewards by now ) have probably moved on to other shares that promise quicker rewards.

What we need is an interview with Scancell that can generate the kind of interest that gets the story out to a much wider audience. Until then the SP can go up and down on very thin trading.

Chester.

Morning WTP

There was a promise in the past and confirmed at the AGM that the early Safety and Immunogenicity data would be released.
It is also necessary so the trial can be approved to move forward to Cohort 4 plus Ci plus higher doses perhaps.

Chester.

Let's just say that 'Stable' means 'Brought under Control'.

That the tumour is no longer advancing at Warp speed.
As has been pointed out, how
do you actually measure a misshaped mass accurately.

You can't count the cells but you can evidence the slowing growth.... Maybe 'Stable' is not a term we non medics understand correctly.

Chester.

Modi1 has to make first contact with the tumour then infiltrate to cause inflammation.
It then causes CD4 cytotoxic T Cells to multiply which begin clearing stressed tumour cells.

This whole process is in billions of cells in a large tumour mass.

Without our treatment the tumour is expanding at a very rapid rate. So come on guys give our hard working Modi1 a break and realise that even stopping the tumours advancement inside 8 weeks, is an unbelievable step forward for these patients and all the potential future sufferers of these awful cancers.

This Scancell RNS is really fantastic news showing that our technology really does work with the human immune system.
Early days but its working ......

Chester.

Really does relate to Moditope, thank you Burble.

Makes today's RNS information even more exciting....

Chester.

There are events or moments in time that when you look back later you realise that they marked a point where things changed.

Today will be seen as one of those moments.

A new and potentially potent cancer treatment has just had its scientific baptism.

Chester.

But we have been told today that we've just taken one giant step towards a future where you will see some of your hopes come true.

If you think where all of those patients could be in 3 months time, that's when I'm expecting Scancell to open up and be more confident in their language.

Chester.

Hi Matt and rigga

This is only where each patient was at their individual first scan.

It's not a 'where we are at' RNS it's a line in the sand just covering Safety and Immunogenicity on first checkup.

The company knows the full picture, the new Chairman knows the full picture and the patients who are 6 months into their treatment know the full picture.

These results across 14 patients at only 8 weeks are remarkable considering what they faced without being part of the ModiFY trial.

No need to be down hearted.

Chester.

Scancell chose to go up against four solid tumour cancers that stand out as difficult to treat.

Patients at late stage with these cancers have no options left so these early indications are life changing for some.

The 8 weeks Safety and Immunogenicity data is just the beginning of our journey as there is so much more to come from the basket design of the ModiFY Trial.

Hugely happy with the details in this announcement.

Chester.

Also just as important is the fact that Modi1 is not creating the awful side effects that Ci's induce.
The wider market may not react to 'Encouraging' but the reality is Modi1 is working, Early (8 weeks), its Safe and this is Stabilising aggressive terminal tumours.

Scientific 'Encouraging' reads 'Simply Fantastic' to me.

Chester.

chillpill1 you are correct, the results in the report covers just 14 patients.

This report is taking a snap shot at 8 weeks across 14 patients. In essence we are being told that after 2 months what the status is at first scan.
Scancell again not getting ahead of themselves and presenting a solid safety and Immunogenicity report.

This is a very Encouraging place to be at 8 weeks.

Chester.